Related Experiment Video

Updated: Aug 16, 2026

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

Receptor-targeted cancer therapy

Mark Richter1, Hongtao Zhang

  • 1Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA 19104-6082, USA.

DNA and Cell Biology
|May 5, 2005
PubMed

Insights

Targeted cancer therapies disrupt oncogenic signaling pathways, offering greater tumor selectivity and fewer side effects than traditional chemotherapy. Research focuses on novel ErbB-directed agents targeting receptor interactions for improved cancer treatment.

Area of Science:

  • Molecular oncology and targeted cancer therapy.
  • Cell surface receptor signaling pathways.

Background:

  • Conventional cancer treatments targeting DNA cause significant toxicity and drug resistance.
  • Targeted strategies offer improved selectivity by disrupting oncogenic signaling molecules.
  • ErbB receptor signaling is implicated in numerous cancers, correlating with poor prognosis.

Purpose of the Study:

  • To review the evolution and promise of ErbB-directed targeted cancer therapies.
  • To highlight advancements in targeting receptor tyrosine kinases and their interactions.

Main Methods:

  • Review of targeted therapy development, including monoclonal antibodies and small molecule inhibitors.
  • Focus on strategies disrupting ErbB receptor signaling pathways (e.g., HER-2/neu, EGFR).
  • Exploration of novel approaches targeting receptor oligomeric complexes.

Main Results:

  • Monoclonal antibodies targeting ErbB receptors (HER-2/neu, EGFR) demonstrated early success in targeted therapy.
  • Small molecule inhibitors targeting the ErbB tyrosine kinase domain are effective.
  • Ongoing development shows promise for novel ErbB-directed entities.

Conclusions:

  • Targeted therapies, particularly those directed at ErbB receptors, offer improved cancer treatment outcomes.
  • Strategies inhibiting receptor interactions within oligomeric complexes represent a promising future direction.

More Related Videos

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer10:46

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer

Published on: September 13, 2022

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Receptor Tyrosine Kinases01:26

Receptor Tyrosine Kinases

Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.